123
+4.24%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Perseus Proteomics
Its shares trade on Tokyo Stock Exchange under the ticker 4882.T. It has been listed since 22 June 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥135.5m and a net loss of ¥718.1m. At that date it held total assets of ¥1.62bn and shareholders' equity of ¥1.22bn.
Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Jun 2021
- Employees
- 24
- Website
- ppmx.com ↗
Leadership
Pay as last reported
- Mr. Takuya YokokawaPresident, Chief Executive Officer, Executive Officer, Representative Director, since 2018
- Mr. Shinichi SuzukawaExecutive Officer, Director of Administration, Director, since 2020
- Mr. Shinji HagiwaraExecutive Officer, Director of Research and Development, Director of Business Development, Director, since 2023
- Mr. Tadashi MatsuuraExecutive Officer, since 2019
- Mr. Nobuo HanaiIndependent Director
- Mr. Tadashi HoriuchiIndependent Director
- Mr. Kinichiro KominamiIndependent Director
- Mr. Tatsuya NagaseIndependent Director
- Mr. Takashi OhnoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Perseus Proteomics Inc develops antibody-based therapeutics for cancer with PPMX-T001 targeting glypican 3 on cancer cells.
- The company focuses on R&D for therapeutic drugs and antibody research support in the Health Care sector.
- Perseus Proteomics Inc employs 24 full-time staff in Chuo-Ku, Tokyo-To for biotechnology innovation.
Weaknesses
- Perseus Proteomics Inc has a small workforce of 24 employees in Chuo-Ku, Tokyo-To.
- The company's IPO on 22 June 2021 indicates limited market presence.
- Perseus Proteomics Inc's product portfolio includes only four therapeutic agents like PPMX-T001.
Opportunities
- Perseus Proteomics Inc can expand its antibody research support in the Health Care sector.
- The company may grow through licensing and manufacturing methods for commercialization.
- Perseus Proteomics Inc can leverage its focus on cancer therapeutics for new markets.
Threats
- Perseus Proteomics Inc faces competition from other biotechnology firms in Japan.
- The company must navigate regulatory challenges in the Health Care industry.
- Perseus Proteomics Inc's small size may limit its ability to compete globally.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.